GlassScriptPhysician profile
Nihal K Patel
NPI 1720375090
$8,001.63
in general payments reported to CMS, 2019-2025
37 companies · $2,383 in 2025
The $2,383 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $126 · 2021: $131 · 2022: $791 · 2023: $1,562 · 2024: $2,577 · 2025: $2,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,279 · Education: $193 · Consulting Fee: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,279.32 |
| Education | $192.58 |
| Consulting Fee | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,320.18 | 2019-2025 | |
| Janssen Biotech, INC. | $1,163.17 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $998.68 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $542.63 | 2024-2025 | Voquezna |
| Celgene Corporation | $461.76 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $356.97 | 2023-2025 | Omvoh, Zepbound, Mounjaro |
| Ironwood Pharmaceuticals, INC | $331.64 | 2019-2025 | Linzess |
| Gilead Sciences, INC. | $319.51 | 2019-2025 | Epclusa |
| Ardelyx, INC. | $288.83 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $272.36 | 2019-2025 | |
| Madrigal Pharmaceuticals | $225.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $210.91 | 2024-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $208.05 | 2023-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $173.33 | 2022-2023 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $157.36 | 2022-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $139.56 | 2022 | |
| Evoke Pharma, INC. | $109.61 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $74.80 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $71.69 | 2024-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $60.66 | 2021-2022 | |
| Allergan, INC. | $57.61 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $50.01 | 2020-2025 | |
| Boston Scientific Corporation | $50.00 | 2023 | |
| Intra-Sana Laboratories | $50.00 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Nestle Healthcare Nutrition INC. | $37.83 | 2021-2023 | |
| Pfizer INC. | $33.57 | 2023-2024 | |
| Orphalan INC | $33.12 | 2024 | Cuvrior |
| Aimmune Therapeutics, INC. | $32.07 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $30.56 | 2019 | |
| Novo Nordisk INC | $26.33 | 2025 | Wegovy |
| Exact Sciences Corporation | $25.49 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $23.74 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.99 | 2023 | Cyltezo |
| Celltrion USA INC. | $17.58 | 2024 | Zymfentra |
| Alfasigma USA, INC. | $12.96 | 2020 | |
| Shionogi INC | $12.14 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nihal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.